Donald TrumpDonald TrumpConservatives to Congress: Get moving New York Knicks owner gave 0K to pro-Trump group Spicer: Ivanka Trump's White House role is 'to be helpful and provide input' MORE is calling for Medicare to be able to negotiate with pharmaceutical companies to lower drug prices, a policy long backed by Democrats and opposed by Republicans.
"We don't do it. Why? Because of the drug companies,” Trump said, according to The Associated Press.
Democratic candidates Hillary ClintonHillary Rodham ClintonNew York Knicks owner gave 0K to pro-Trump group Beyoncé voices support for LGBTQ students after Trump transgender order Trump to address GOP donors in Florida: report MORE and Bernie SandersBernie SandersDeVos: 'My job isn’t to win a popularity contest with the media' DNC candidate Harrison drops out, backs Perez for chairman The Hill's 12:30 Report MORE, as well as President Obama, have called for the same policy of letting Medicare negotiate prices, which it is currently banned from doing under the 2003 Medicare prescription drug law. The Democratic candidates have both bashed the drug companies on the stump.
Trump has already broken from Republican orthodoxy on one other major healthcare policy this campaign, defending his past support for single-payer healthcare, long a dream of liberals.
“As far as single payer, it works in Canada,” Trump said at a Republican debate in August. “It works incredibly well in Scotland. It could have worked in a different age.”
Trump then added that he now prefers a “private system” and proposed a standard Republican idea: allowing insurance to be sold across state lines.
The drug pricing proposal comes at a time of increased scrutiny of pharmaceutical companies over high drug prices. There is a bipartisan investigation in the Senate Aging Committee, and the House Oversight Committee subpoenaed former drug company CEO Martin Shkreli, the poster boy for high drug prices, to testify next week.
So far, though, the attention of congressional Republicans has largely been on a handful of companies that have dramatically hiked prices for off-patent drugs facing little market competition, and the outrage has not spread to more mainstream pharmaceutical companies. For example, letting Medicare negotiate prices still appears to have little hope in Congress.